Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 70.19M | 69.28M | 69.56M | 209.91M | 33.92M | 0.00 |
Gross Profit | 63.85M | 63.33M | 67.03M | 205.33M | 32.52M | -1.97M |
EBITDA | -99.25M | -103.71M | -146.76M | -108.06M | -223.72M | -219.26M |
Net Income | -149.84M | -157.85M | -240.05M | -155.80M | -230.03M | -246.29M |
Balance Sheet | ||||||
Total Assets | 272.54M | 321.98M | 354.78M | 490.86M | 617.97M | 513.69M |
Cash, Cash Equivalents and Short-Term Investments | 194.70M | 250.87M | 278.60M | 326.44M | 466.54M | 439.19M |
Total Debt | 334.70M | 123.00M | 124.38M | 117.38M | 101.75M | 41.87M |
Total Liabilities | 510.76M | 524.62M | 503.03M | 411.41M | 451.88M | 178.19M |
Stockholders Equity | -238.22M | -202.64M | -148.25M | 79.45M | 166.09M | 335.50M |
Cash Flow | ||||||
Free Cash Flow | -135.40M | -124.70M | -121.90M | -139.09M | -239.75M | -171.54M |
Operating Cash Flow | -134.81M | -123.83M | -118.69M | -136.79M | -233.38M | -168.73M |
Investing Cash Flow | -590.80K | -867.00K | -3.22M | -2.51M | -6.67M | -2.83M |
Financing Cash Flow | 95.34M | 97.05M | 73.88M | -593.00K | 267.39M | 494.97M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $270.63M | ― | -99.23% | ― | -40.10% | -16.60% | |
52 Neutral | $7.45B | 0.27 | -61.87% | 2.30% | 16.62% | 1.04% | |
51 Neutral | $267.78M | ― | 123.38% | ― | 10.49% | 47.31% | |
49 Neutral | $204.89M | ― | -50.77% | ― | ― | -54.29% | |
39 Underperform | $134.93M | ― | -75.60% | ― | ― | -2.29% | |
36 Underperform | $111.72M | ― | -244.16% | ― | ― | 77.12% | |
28 Underperform | $43.69M | ― | -41.96% | ― | ― | 72.12% |
On June 11, 2025, ADC Therapeutics SA announced a $100 million private placement with institutional investors, selling common shares and pre-funded warrants. This strategic move is aimed at bolstering their financial position and facilitating the company’s focus on expanding ZYNLONTA® and advancing its PSMA-targeting ADC. Concurrently, the company announced a restructuring plan to streamline operations by shutting down its U.K. research facility and reducing its workforce by 30%, with expected completion by September 30, 2025. This restructuring is anticipated to incur one-time pre-tax charges of approximately $6 million to $7 million.
The most recent analyst rating on (ADCT) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on ADC Therapeutics stock, see the ADCT Stock Forecast page.
On June 3, 2025, ADC Therapeutics SA held its annual general meeting where all proposals were approved by shareholders. Key decisions included the approval of financial statements for 2024, discharge of board members from liability, and reelection of directors and auditors. Additionally, amendments to increase share capital for employee participation were sanctioned, reflecting the company’s strategic focus on growth and employee engagement.
The most recent analyst rating on (ADCT) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on ADC Therapeutics stock, see the ADCT Stock Forecast page.